Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Trial Profile

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary) ; CDX 1401 (Primary) ; Poly ICLC
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2017 Status changed from recruiting to withdrawn prior to enrolment.
    • 05 May 2016 Status changed from not yet recruiting to recruiting.
    • 15 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top